Daniel J. Freeman

5.4k total citations · 2 hit papers
40 papers, 3.9k citations indexed

About

Daniel J. Freeman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Daniel J. Freeman has authored 40 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Daniel J. Freeman's work include Colorectal Cancer Treatments and Studies (17 papers), HER2/EGFR in Cancer Research (13 papers) and Lung Cancer Treatments and Mutations (11 papers). Daniel J. Freeman is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), HER2/EGFR in Cancer Research (13 papers) and Lung Cancer Treatments and Mutations (11 papers). Daniel J. Freeman collaborates with scholars based in United States, Japan and Italy. Daniel J. Freeman's co-authors include Robert Radinsky, Todd Juan, Rafael G. Amado, Michael Wolf, Sid Suggs, Scott D. Patterson, Marc Peeters, Eric Van Cutsem, Salvatore Siena and David Chang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Nature Reviews Drug Discovery.

In The Last Decade

Daniel J. Freeman

38 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 2.4k citations Rafael G. Amado, Michael Wolf et al. Journal of Clinical Oncology profile →
Optimizing oncolytic virotherapy in cancer treatment

2019 384 citations Kevin J. Harrington, Daniel J. Freeman et al. Nature Reviews Drug Discovery profile →

Peers

Countries citing papers authored by Daniel J. Freeman

Since Specialization

Citations

This map shows the geographic impact of Daniel J. Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Freeman more than expected).

Fields of papers citing papers by Daniel J. Freeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel J. Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Freeman. The network helps show where Daniel J. Freeman may publish in the future.

Co-authorship network of co-authors of Daniel J. Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel J. Freeman. A scholar is included among the top collaborators of Daniel J. Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel J. Freeman. Daniel J. Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	terraFlow, a high-parameter analysis tool, reveals T cell exhaustion and dysfunctional cytokine production in classical Hodgkin’s lymphoma 2024 ·Cell Reports ·Daniel J. Freeman, Catherine Diefenbach, Linda Lam, Tri D. Le, (unknown), Bruce G. Raphael, Michael L. Grossbard, David Kaminetzky, Jia Ruan, Pratip K. Chattopadhyay	3
2	Intervention strategies for microbial therapeutics in cancer immunotherapy 2020 ·Immuno-Oncology Technology ·Vancheswaran Gopalakrishnan, Bryan J. Weiner, Christopher B. Ford, Bret R. Sellman, Scott A. Hammond, Daniel J. Freeman, Phillip A. Dennis, J.C. Soria, Jennifer R. Wortman, Matthew R. Henn	11
3	Optimizing oncolytic virotherapy in cancer treatment breakdown → 2019 ·Nature Reviews Drug Discovery ·Kevin J. Harrington, Daniel J. Freeman, Elizabeth J. Kelly, James A. Harper, Jean‐Charles Soria	384
4	Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non–Small Cell Lung Cancer Tissue 2017 ·Biomarker Insights ·(unknown), (unknown), Xiaoping Jin, Kenji Nakamaru, Matthias Schneider, Robert A. Beckman, Daniel J. Freeman, (unknown), Wenqin Feng	4
5	Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer 2015 ·EBioMedicine ·Jeanne Mendell, Daniel J. Freeman, Wenqin Feng, Thore Hettmann, Matthias Schneider, Sabine Blum, Jens E. Ruhe, Johannes Bange, Kenji Nakamaru, Shuquan Chen, Zenta Tsuchihashi, Joachim von Pawel, Catherine Copigneaux, Robert A. Beckman	30
6	Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models 2013 ·Neoplasia ·Michael Boedigheimer, Daniel J. Freeman, (unknown), Michael A. Damore, Robert Radinsky	5
7	A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer 2013 ·Journal of Thoracic Oncology ·Jeffrey Crawford, Paul Swanson, Paul Schwarzenberger, Alan Sandler, Diane Prager, Kathy Zhang, Daniel J. Freeman, Carol W. Johnson, Kartik Krishnan, David H. Johnson	18
8	Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer 2012 ·Molecular Cancer ·Daniel J. Freeman, Kevin S. McDorman, (unknown), Carl J. Kozlosky, Bingbing Yang, Sameer Doshi, (unknown), William C. Fanslow, Charlie Starnes, Robert Radinsky	24
9	Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold 2012 ·Bioorganic & Medicinal Chemistry Letters ·Ryan P. Wurz, Longbin Liu, Kevin Yang, Nobuko Nishimura, Yunxin Bo, Liping H. Pettus, Sean Caenepeel, Daniel J. Freeman, John D. McCarter, Erin L. Mullady, Tisha San Miguel, Ling Wang, Nancy R. Zhang, Kristin L. Andrews, Douglas A. Whittington, Jian Jiang, Raju Subramanian, Paul E. Hughes, Mark H. Norman	23
10	Probing the Role of the Linker in Ferrocene–ATP Conjugates: Monitoring Protein Kinase Catalyzed Phosphorylations Electrochemically 2011 ·Chemistry - A European Journal ·Sanela Martić, Mahmoud Labib, Daniel J. Freeman, Heinz‐Bernhard Kraatz	34
11	Use of 5′-γ-Ferrocenyl Adenosine Triphosphate (Fc-ATP) Bioconjugates Having Poly(ethylene glycol) Spacers in Kinase-Catalyzed Phosphorylations 2011 ·Bioconjugate Chemistry ·Sanela Martić, (unknown), Daniel J. Freeman, Heinz‐Bernhard Kraatz	19
12	2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics 2010 ·Bioorganic & Medicinal Chemistry Letters ·Qingping Zeng, Matthew P. Bourbeau, (unknown), (unknown), Holger Monenschein, (unknown), Matthew R. Lee, Shiwen Zhang, Julie A. Lofgren, Daniel J. Freeman, Chun Li, (unknown), Xin Huang, Douglas W. Hoffman, Harvey Yamane, Andrew S. Tasker, Celia Dominguez, Vellarkad N. Viswanadhan, Randall W. Hungate, Xiaoling Zhang	15
13	A comparability study of 5 commercial KRAS tests 2010 ·Diagnostic Pathology ·Kelly S. Oliner, Todd Juan, Sid Suggs, Michael Wolf, Ildiko Sarosi, Daniel J. Freeman, Tibor Gyuris, (unknown), Andreas Bakker, Alex Parker, Scott D. Patterson	44
14	Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer breakdown → 2008 ·Journal of Clinical Oncology ·Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David Chang	2400
15	Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors 2008 ·Cancer Research ·Daniel J. Freeman, (unknown), Mike Rothe, Robert Radinsky, Martin Treder	19
16	Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract Cancer 2008 ·International Journal of Radiation OncologyBiologyPhysics ·Tim J. Kruser, Eric A. Armstrong, Amol J. Ghia, Shyhmin Huang, Deric L. Wheeler, Robert Radinsky, Daniel J. Freeman, Paul M. Harari	34
17	Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone 2008 ·Clinical Colorectal Cancer ·Daniel J. Freeman, Todd Juan, Maureen Reiner, J. Randolph Hecht, Neal J. Meropol, Jordan Berlin, Edith P. Mitchell, Ildiko Sarosi, Robert Radinsky, Rafael G. Amado	129
18	7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy 2007 ·European Journal of Cancer Supplements ·Rafael G. Amado, Michael Wolf, Daniel J. Freeman, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Sidney V. Suggs, (unknown), D. Chang	17
19	PTEN Regulates Mdm2 Expression through the P1 Promoter 2004 ·Journal of Biological Chemistry ·Chun-Ju Chang, Daniel J. Freeman, Hong Wu	81
20	PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms 2003 ·Cancer Cell ·Daniel J. Freeman, (unknown), Gang Wei, (unknown), Nathalie Kertesz, Ralf Lesche, Andrew Whale, Hilda Martinez-Diaz, Nora Rozengurt, Robert D. Cardiff, Xuan Liu, Hong Wu	403

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact